公司資料
PolyPid 股價、新聞與催化劑
- 股票代碼:
- PYPD
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Israel
股票表現
4.77 USD (+0.63%)
收盤價
最後更新: 2026年8月17日
93.4M USD
市值
股價為何變動
As of Aug 17, 2026, PYPD closed up 0.63% at $4.77. No new same-company headline was identified in the current news window.
公司概覽
Local Controlled-Release Therapeutics
PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site. This approach is intended to improve local exposure while limiting systemic treatment burden.
PLEX Technology
The PLEX platform embeds drugs within a biodegradable polymer-lipid matrix to control local release over days or weeks.
D-PLEX100
D-PLEX100 delivers doxycycline locally after abdominal colorectal surgery to prevent surgical-site infections. Its NDA is supported by the pivotal Phase 3 SHIELD II study, which met its primary and key secondary endpoints.
Azurity Partnership
Azurity Pharmaceuticals holds U.S. and Canadian commercialization rights to D-PLEX100. PolyPid retains eligibility for development and commercial milestones plus tiered royalties.
未來催化劑
- FDA action on the D-PLEX100 NDA by the November 28, 2026 PDUFA goal date.
- Potential U.S. commercial launch of D-PLEX100 by Azurity in early 2027, subject to approval.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。